ArticleFrontiers in neuroscience2026
Two-year longitudinal neuropsychological monitoring after unilateral and staged bilateral subthalamic nucleus deep brain stimulation.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Deep brain stimulation (DBS) is an increasingly popular therapeutic method for treating motor symptoms in Parkinson's disease, but its impact on non-motor symptoms in long-term follow-up remains debated. Method: The primary objective of this study was to monitor the cognitive functioning, mood, and quality of life in 2 years of unilateral and staged bilateral subthalamic nucleus DBS. A cohort of 30 patients was evaluated at three intervals: before DBS surgery, at 6 months, and 24 months post-surgery. The time points of neuropsychological assessments were set to control the impact of unilateral and bilateral DBS throughout the treatment. Two selected groups, unilateral and bilateral DBS, were also analyzed. The study employed a combination of computerized and paper-based tests to assess cognitive functions, alongside questionnaires to gauge emotional state and quality of life. The cognitive evaluation focused on three domains critical for daily activities: attention and processing speed, learning and episodic memory, and executive functions, including working memory and cognitive flexibility. Results: Analysis of the entire cohort from baseline through the two follow-up assessments revealed no decline in cognitive function, mood, or quality of life, alongside significant motor improvement. Additional analyses of the two subgroups-unilateral DBS and staged bilateral DBS-also showed no overall decline in any assessed domain over the 2-year follow-up period. However, comparison of cognitive outcomes with normative data indicated a higher proportion of patients meeting criteria for cognitive decline at the 24-month follow-up in the staged bilateral DBS group compared with the unilateral DBS group. Conclusion: The findings support the long-term overall stability of cognitive function, mood, and quality of life following unilateral and staged bilateral subthalamic DBS. Subgroup analyses did not reveal any significant decline in cognitive measures over time. Nevertheless, individual comparisons with normative data showed a higher proportion of patients with memory deficits in the staged bilateral DBS group after the two-year follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.